Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial for HCV treatment with bemnifosbuvir and ruzasvir.

Atea Pharmaceuticals announced the ongoing enrollment in its Phase 3 C-BEYOND trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). Positive ...

The recognition of HIV ssRNA by TLR7 in pDCs activates the MYD88 pathway, stimulating IRF7 and IFN-α secretion (Table 5). 112 Disease progression is, however, associated with a decrease in pDCs and a ...

There are no approved treatments for post-COVID-19 condition (also known as long COVID), a debilitating disease state following SARS-CoV-2 infection that is estimated to affect tens of millions of ...

DDX1 is a human DEAD-box RNA helicase involved in various stages of RNA metabolism, from transcription to decay, and is consequently implicated in many human diseases. The nucleotides hydrolyzed by ...

Here, we observed a TLR4-and TRL8-dependent DC activation following exposure to NLC-Ova mRNA. This is probably linked to the cationic lipid composition of the Lipidots® and the ssRNA form of mRNA, ...

The recent discovery of non-proteinaceous ubiquitylation substrates broadened our understanding of this modification beyond conventional protein targets. However, the existence of additional types of ...

This SP- and ssRNA-induced Tlr7 gene expression signature was associated with reduced breast cancer survival outcomes. Therapeutic targeting of this neuro–cancer axis with the TACR1 antagonist ...

CRISPR-Cas13 also indiscriminately cleaves single-stranded RNA (ssRNA) when engaged at its RNA target sequence. This RNA-targeting ability makes it perfect for targeting mRNA and is useful as a ...

In diagnostics, this property is exploited by introducing a ssDNA (for Cas12) or ssRNA (for Cas13) reporter molecule into the reaction. When Cas12 or Cas13 finds and cleaves its target, it also ...